Pharma & Healthcare
Global Hyperimmune Globulins Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
- Jun 12, 25
- ID: 307493
- Pages: 141
- Figures: 150
- Views: 2
In 2024, the global market size of Hyperimmune Globulins was estimated to be worth US$ 1936 million and is forecast to reach approximately US$ 3089 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Global Hyperimmune Globulins key players include CSL Behring, Grifols, etc. Global top two manufacturers hold a share over 50%. Asia-Pacific is the largest market, with a share about 30%, followed by Europe and North America, both have a share over 50 percent. In terms of product, Rho(D) Immunoglobulins is the largest segment, with a share about 33%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.
The hyperimmune globulin market is primarily driven by the increasing prevalence of infectious diseases and the rising demand for immunoglobulin therapies. These therapies are crucial in treating immunodeficiency disorders and providing passive immunity against various pathogens, which fuels market growth. Additionally, advancements in plasma-derived therapies and increasing government initiatives for immunization programs contribute to market expansion.
However, the market faces significant challenges, such as the high cost of treatment and limited availability of plasma, which is a critical raw material for hyperimmune globulin production. Moreover, stringent regulatory requirements for product approval and potential side effects associated with immunoglobulin therapies can hinder market growth.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hyperimmune Globulins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hyperimmune Globulins.
The Hyperimmune Globulins market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hyperimmune Globulins market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hyperimmune Globulins manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.
By Company
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Herpes Zoster Immune Globulin
Other
Segment by Application
Government Institutions
Private Sector
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Hyperimmune Globulins in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Hyperimmune Globulins manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hyperimmune Globulins sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Global Hyperimmune Globulins key players include CSL Behring, Grifols, etc. Global top two manufacturers hold a share over 50%. Asia-Pacific is the largest market, with a share about 30%, followed by Europe and North America, both have a share over 50 percent. In terms of product, Rho(D) Immunoglobulins is the largest segment, with a share about 33%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.
The hyperimmune globulin market is primarily driven by the increasing prevalence of infectious diseases and the rising demand for immunoglobulin therapies. These therapies are crucial in treating immunodeficiency disorders and providing passive immunity against various pathogens, which fuels market growth. Additionally, advancements in plasma-derived therapies and increasing government initiatives for immunization programs contribute to market expansion.
However, the market faces significant challenges, such as the high cost of treatment and limited availability of plasma, which is a critical raw material for hyperimmune globulin production. Moreover, stringent regulatory requirements for product approval and potential side effects associated with immunoglobulin therapies can hinder market growth.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hyperimmune Globulins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hyperimmune Globulins.
The Hyperimmune Globulins market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hyperimmune Globulins market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hyperimmune Globulins manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.
By Company
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Herpes Zoster Immune Globulin
Other
Segment by Application
Government Institutions
Private Sector
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Hyperimmune Globulins in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Hyperimmune Globulins manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hyperimmune Globulins sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
1 Study Coverage
1.1 Hyperimmune Globulins Product Introduction
1.2 Market by Type
1.2.1 Global Hyperimmune Globulins Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Hepatitis B Immunoglobulins
1.2.3 Rabies Immunoglobulins
1.2.4 Tetanus Immunoglobulins
1.2.5 Rho(D) Immunoglobulins
1.2.6 Herpes Zoster Immune Globulin
1.2.7 Other
1.3 Market by Application
1.3.1 Global Hyperimmune Globulins Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Government Institutions
1.3.3 Private Sector
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Hyperimmune Globulins Market Size Estimates and Forecasts
2.1.1 Global Hyperimmune Globulins Revenue 2020-2031
2.1.2 Global Hyperimmune Globulins Sales 2020-2031
2.2 Hyperimmune Globulins Market Size by Region: 2024 Versus 2031
2.3 Hyperimmune Globulins Sales by Region (2020-2031)
2.3.1 Global Hyperimmune Globulins Sales by Region: 2020-2025
2.3.2 Global Hyperimmune Globulins Sales Forecast by Region (2026-2031)
2.3.3 Global Hyperimmune Globulins Sales Market Share by Region (2020-2031)
2.4 Hyperimmune Globulins Market Estimates and Projections by Region (2026-2031)
2.4.1 Global Hyperimmune Globulins Revenue by Region: 2020-2025
2.4.2 Global Hyperimmune Globulins Revenue Forecast by Region (2026-2031)
2.4.3 Global Hyperimmune Globulins Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Hyperimmune Globulins Sales by Type (2020-2031)
3.1.1.1 Global Hyperimmune Globulins Sales Volume by Type (2020-2031)
3.1.1.2 Global Hyperimmune Globulins Sales Market Share by Type (2020-2031)
3.1.2 Global Hyperimmune Globulins Revenue by Type (2020-2031)
3.1.2.1 Global Hyperimmune Globulins Revenue by Type (2020-2031)
3.1.2.2 Global Hyperimmune Globulins Revenue Market Share by Type (2020-2031)
3.1.3 Hyperimmune Globulins Average Selling Price (ASP) by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Hyperimmune Globulins Sales by Application (2020-2031)
3.2.1.1 Global Hyperimmune Globulins Sales Volume by Application (2020-2031)
3.2.1.2 Global Hyperimmune Globulins Sales Market Share by Application (2020-2031)
3.2.2 Global Hyperimmune Globulins Revenue by Application (2020-2031)
3.2.2.1 Global Hyperimmune Globulins Revenue by Application (2020-2031)
3.2.2.2 Global Hyperimmune Globulins Revenue Market Share by Application (2020-2031)
3.2.3 Hyperimmune Globulins Average Selling Price (ASP) by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Hepatitis B Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application
3.3.2 Rabies Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application
3.3.3 Tetanus Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application
3.3.4 Rho(D) Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application
3.3.5 Herpes Zoster Immune Globulin of Hyperimmune Globulins Revenue Market Share by Application
3.3.6 Other of Hyperimmune Globulins Revenue Market Share by Application
4 Global Hyperimmune Globulins by Manufacturers
4.1 Global Top Hyperimmune Globulins Manufacturers by Sales (2020-2025)
4.1.1 Global Hyperimmune Globulins Sales by Manufacturer (2020-2025)
4.1.2 Global Hyperimmune Globulins Sales Market Share by Manufacturer (2020-2025)
4.2 Global Top Hyperimmune Globulins Manufacturers by Revenue (2020-2025)
4.2.1 Global Hyperimmune Globulins Revenue by Manufacturer (2020-2025)
4.2.2 Global Hyperimmune Globulins Revenue Share by Manufacturer (2020-2025)
4.3 Global Hyperimmune Globulins Price by Manufacturer (2020-2025)
4.4 Competitive Landscape
4.4.1 Key Hyperimmune Globulins Manufacturers Covered: Ranking by Revenue
4.4.2 Global Hyperimmune Globulins Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.4.3 Global Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5 Global Hyperimmune Globulins Manufacturing Base Distribution, Product Type
4.5.1 Hyperimmune Globulins Manufacturers Manufacturing Base Distribution, Headquarters
4.5.2 Date of International Manufacturers Enter into Hyperimmune Globulins Market
4.5.3 Manufacturers Hyperimmune Globulins Product Type and Application
4.5.4 Hepatitis B Immunoglobulins Market Sales of Hyperimmune Globulins by Manufacturer
4.5.5 Rabies Immunoglobulins Market Sales of Hyperimmune Globulins by Manufacturer
4.5.6 Tetanus Immunoglobulins Market Sales of Hyperimmune Globulins by Manufacturer
4.5.7 Rho(D) Immunoglobulins Market Sales of Hyperimmune Globulins by Manufacturer
4.5.8 Herpes Zoster Immune Globulin Market Sales of Hyperimmune Globulins by Manufacturer
4.5.9 Other Market Sales of Hyperimmune Globulins by Manufacturer
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 CSL Behring
5.1.1 CSL Behring Company Information
5.1.2 CSL Behring Description, Business Overview
5.1.3 CSL Behring Hyperimmune Globulins Products Offered
5.1.4 CSL Behring Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.1.5 CSL Behring Hyperimmune Globulins Sales by Product in 2024
5.1.6 CSL Behring Hyperimmune Globulins Sales by Application in 2024
5.1.7 CSL Behring Hyperimmune Globulins Sales by Geographic Area in 2024
5.1.8 CSL Behring Recent Developments
5.2 Grifols
5.2.1 Grifols Company Information
5.2.2 Grifols Description, Business Overview
5.2.3 Grifols Hyperimmune Globulins Products Offered
5.2.4 Grifols Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.2.5 Grifols Hyperimmune Globulins Sales by Product in 2024
5.2.6 Grifols Hyperimmune Globulins Sales by Application in 2024
5.2.7 Grifols Hyperimmune Globulins Sales by Geographic Area in 2024
5.2.8 Grifols Recent Developments
5.3 Biotest
5.3.1 Biotest Company Information
5.3.2 Biotest Description, Business Overview
5.3.3 Biotest Hyperimmune Globulins Products Offered
5.3.4 Biotest Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.3.5 Biotest Hyperimmune Globulins Sales by Product in 2024
5.3.6 Biotest Hyperimmune Globulins Sales by Application in 2024
5.3.7 Biotest Hyperimmune Globulins Sales by Geographic Area in 2024
5.3.8 Biotest Recent Developments
5.4 Kedrion
5.4.1 Kedrion Company Information
5.4.2 Kedrion Description, Business Overview
5.4.3 Kedrion Hyperimmune Globulins Products Offered
5.4.4 Kedrion Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.4.5 Kedrion Hyperimmune Globulins Sales by Product in 2024
5.4.6 Kedrion Hyperimmune Globulins Sales by Application in 2024
5.4.7 Kedrion Hyperimmune Globulins Sales by Geographic Area in 2024
5.4.8 Kedrion Recent Developments
5.5 CBPO
5.5.1 CBPO Company Information
5.5.2 CBPO Description, Business Overview
5.5.3 CBPO Hyperimmune Globulins Products Offered
5.5.4 CBPO Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.5.5 CBPO Hyperimmune Globulins Sales by Product in 2024
5.5.6 CBPO Hyperimmune Globulins Sales by Application in 2024
5.5.7 CBPO Hyperimmune Globulins Sales by Geographic Area in 2024
5.5.8 CBPO Recent Developments
5.6 Emergent (Cangene)
5.6.1 Emergent (Cangene) Company Information
5.6.2 Emergent (Cangene) Description, Business Overview
5.6.3 Emergent (Cangene) Hyperimmune Globulins Products Offered
5.6.4 Emergent (Cangene) Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.6.5 Emergent (Cangene) Hyperimmune Globulins Sales by Product in 2024
5.6.6 Emergent (Cangene) Hyperimmune Globulins Sales by Application in 2024
5.6.7 Emergent (Cangene) Hyperimmune Globulins Sales by Geographic Area in 2024
5.6.8 Emergent (Cangene) Recent Developments
5.7 Kamada
5.7.1 Kamada Company Information
5.7.2 Kamada Description, Business Overview
5.7.3 Kamada Hyperimmune Globulins Products Offered
5.7.4 Kamada Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.7.5 Kamada Hyperimmune Globulins Sales by Product in 2024
5.7.6 Kamada Hyperimmune Globulins Sales by Application in 2024
5.7.7 Kamada Hyperimmune Globulins Sales by Geographic Area in 2024
5.7.8 Kamada Recent Developments
5.8 CNBG
5.8.1 CNBG Company Information
5.8.2 CNBG Description, Business Overview
5.8.3 CNBG Hyperimmune Globulins Products Offered
5.8.4 CNBG Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.8.5 CNBG Hyperimmune Globulins Sales by Product in 2024
5.8.6 CNBG Hyperimmune Globulins Sales by Application in 2024
5.8.7 CNBG Hyperimmune Globulins Sales by Geographic Area in 2024
5.8.8 CNBG Recent Developments
5.9 Hualan Bio
5.9.1 Hualan Bio Company Information
5.9.2 Hualan Bio Description, Business Overview
5.9.3 Hualan Bio Hyperimmune Globulins Products Offered
5.9.4 Hualan Bio Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.9.5 Hualan Bio Hyperimmune Globulins Sales by Product in 2024
5.9.6 Hualan Bio Hyperimmune Globulins Sales by Application in 2024
5.9.7 Hualan Bio Hyperimmune Globulins Sales by Geographic Area in 2024
5.9.8 Hualan Bio Recent Developments
5.10 Shanghai RAAS
5.10.1 Shanghai RAAS Company Information
5.10.2 Shanghai RAAS Description, Business Overview
5.10.3 Shanghai RAAS Hyperimmune Globulins Products Offered
5.10.4 Shanghai RAAS Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.10.5 Shanghai RAAS Hyperimmune Globulins Sales by Product in 2024
5.10.6 Shanghai RAAS Hyperimmune Globulins Sales by Application in 2024
5.10.7 Shanghai RAAS Hyperimmune Globulins Sales by Geographic Area in 2024
5.10.8 Shanghai RAAS Recent Developments
5.11 Sichuan Yuanda Shuyang
5.11.1 Sichuan Yuanda Shuyang Company Information
5.11.2 Sichuan Yuanda Shuyang Description, Business Overview
5.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulins Products Offered
5.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.11.5 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales by Product in 2024
5.11.6 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales by Application in 2024
5.11.7 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales by Geographic Area in 2024
5.11.8 Sichuan Yuanda Shuyang Recent Developments
5.12 ADMA Biologics
5.12.1 ADMA Biologics Company Information
5.12.2 ADMA Biologics Description, Business Overview
5.12.3 ADMA Biologics Hyperimmune Globulins Products Offered
5.12.4 ADMA Biologics Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.12.5 ADMA Biologics Hyperimmune Globulins Sales by Product in 2024
5.12.6 ADMA Biologics Hyperimmune Globulins Sales by Application in 2024
5.12.7 ADMA Biologics Hyperimmune Globulins Sales by Geographic Area in 2024
5.12.8 ADMA Biologics Recent Developments
6 North America
6.1 North America Hyperimmune Globulins Market Size YoY Growth 2020-2031
6.2 North America Hyperimmune Globulins Market Facts & Figures by Country
6.2.1 North America Hyperimmune Globulins Sales by Country (2020-2031)
6.2.2 North America Hyperimmune Globulins Revenue by Country (2020-2031)
6.3 North America Hyperimmune Globulins Sales by Type (2020-2025)
6.4 North America Hyperimmune Globulins Sales by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Hyperimmune Globulins Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Hyperimmune Globulins Market Facts & Figures by Region
7.2.1 Asia-Pacific Hyperimmune Globulins Sales by Region (2020-2031)
7.2.2 Asia-Pacific Hyperimmune Globulins Revenue by Region (2020-2031)
7.3 Asia-Pacific Hyperimmune Globulins Sales by Type (2020-2025)
7.4 Asia-Pacific Hyperimmune Globulins Sales by Application (2020-2025)
8 Europe
8.1 Europe Hyperimmune Globulins Market Size YoY Growth 2020-2031
8.2 Europe Hyperimmune Globulins Market Facts & Figures by Country
8.2.1 Europe Hyperimmune Globulins Sales by Country (2020-2031)
8.2.2 Europe Hyperimmune Globulins Revenue by Country (2020-2031)
8.3 Europe Hyperimmune Globulins Sales by Type (2020-2025)
8.4 Europe Hyperimmune Globulins Sales by Application (2020-2025)
9 Latin America
9.1 Latin America Hyperimmune Globulins Market Size YoY Growth 2020-2031
9.2 Latin America Hyperimmune Globulins Market Facts & Figures by Country
9.2.1 Latin America Hyperimmune Globulins Sales by Country (2020-2031)
9.2.2 Latin America Hyperimmune Globulins Revenue by Country (2020-2031)
9.3 Latin America Hyperimmune Globulins Sales by Type (2020-2025)
9.4 Latin America Hyperimmune Globulins Sales by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Hyperimmune Globulins Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Hyperimmune Globulins Market Facts & Figures by Country
10.2.1 Middle East and Africa Hyperimmune Globulins Sales by Country (2020-2031)
10.2.2 Middle East and Africa Hyperimmune Globulins Revenue by Country (2020-2031)
10.3 Middle East and Africa Hyperimmune Globulins Sales by Type (2020-2025)
10.4 Middle East and Africa Hyperimmune Globulins Sales by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Hyperimmune Globulins Supply Chain Analysis
11.2 Hyperimmune Globulins Key Raw Materials and Upstream Suppliers
11.3 Hyperimmune Globulins Clients Analysis
11.4 Hyperimmune Globulins Sales Channel and Sales Model Analysis
11.4.1 Hyperimmune Globulins Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Hyperimmune Globulins Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Hyperimmune Globulins Distributors
12 Hyperimmune Globulins Market Dynamics
12.1 Hyperimmune Globulins Industry Trends
12.2 Hyperimmune Globulins Market Drivers
12.3 Hyperimmune Globulins Market Challenges
12.4 Hyperimmune Globulins Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 Hyperimmune Globulins Product Introduction
1.2 Market by Type
1.2.1 Global Hyperimmune Globulins Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Hepatitis B Immunoglobulins
1.2.3 Rabies Immunoglobulins
1.2.4 Tetanus Immunoglobulins
1.2.5 Rho(D) Immunoglobulins
1.2.6 Herpes Zoster Immune Globulin
1.2.7 Other
1.3 Market by Application
1.3.1 Global Hyperimmune Globulins Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Government Institutions
1.3.3 Private Sector
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Hyperimmune Globulins Market Size Estimates and Forecasts
2.1.1 Global Hyperimmune Globulins Revenue 2020-2031
2.1.2 Global Hyperimmune Globulins Sales 2020-2031
2.2 Hyperimmune Globulins Market Size by Region: 2024 Versus 2031
2.3 Hyperimmune Globulins Sales by Region (2020-2031)
2.3.1 Global Hyperimmune Globulins Sales by Region: 2020-2025
2.3.2 Global Hyperimmune Globulins Sales Forecast by Region (2026-2031)
2.3.3 Global Hyperimmune Globulins Sales Market Share by Region (2020-2031)
2.4 Hyperimmune Globulins Market Estimates and Projections by Region (2026-2031)
2.4.1 Global Hyperimmune Globulins Revenue by Region: 2020-2025
2.4.2 Global Hyperimmune Globulins Revenue Forecast by Region (2026-2031)
2.4.3 Global Hyperimmune Globulins Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Hyperimmune Globulins Sales by Type (2020-2031)
3.1.1.1 Global Hyperimmune Globulins Sales Volume by Type (2020-2031)
3.1.1.2 Global Hyperimmune Globulins Sales Market Share by Type (2020-2031)
3.1.2 Global Hyperimmune Globulins Revenue by Type (2020-2031)
3.1.2.1 Global Hyperimmune Globulins Revenue by Type (2020-2031)
3.1.2.2 Global Hyperimmune Globulins Revenue Market Share by Type (2020-2031)
3.1.3 Hyperimmune Globulins Average Selling Price (ASP) by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Hyperimmune Globulins Sales by Application (2020-2031)
3.2.1.1 Global Hyperimmune Globulins Sales Volume by Application (2020-2031)
3.2.1.2 Global Hyperimmune Globulins Sales Market Share by Application (2020-2031)
3.2.2 Global Hyperimmune Globulins Revenue by Application (2020-2031)
3.2.2.1 Global Hyperimmune Globulins Revenue by Application (2020-2031)
3.2.2.2 Global Hyperimmune Globulins Revenue Market Share by Application (2020-2031)
3.2.3 Hyperimmune Globulins Average Selling Price (ASP) by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Hepatitis B Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application
3.3.2 Rabies Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application
3.3.3 Tetanus Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application
3.3.4 Rho(D) Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application
3.3.5 Herpes Zoster Immune Globulin of Hyperimmune Globulins Revenue Market Share by Application
3.3.6 Other of Hyperimmune Globulins Revenue Market Share by Application
4 Global Hyperimmune Globulins by Manufacturers
4.1 Global Top Hyperimmune Globulins Manufacturers by Sales (2020-2025)
4.1.1 Global Hyperimmune Globulins Sales by Manufacturer (2020-2025)
4.1.2 Global Hyperimmune Globulins Sales Market Share by Manufacturer (2020-2025)
4.2 Global Top Hyperimmune Globulins Manufacturers by Revenue (2020-2025)
4.2.1 Global Hyperimmune Globulins Revenue by Manufacturer (2020-2025)
4.2.2 Global Hyperimmune Globulins Revenue Share by Manufacturer (2020-2025)
4.3 Global Hyperimmune Globulins Price by Manufacturer (2020-2025)
4.4 Competitive Landscape
4.4.1 Key Hyperimmune Globulins Manufacturers Covered: Ranking by Revenue
4.4.2 Global Hyperimmune Globulins Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.4.3 Global Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5 Global Hyperimmune Globulins Manufacturing Base Distribution, Product Type
4.5.1 Hyperimmune Globulins Manufacturers Manufacturing Base Distribution, Headquarters
4.5.2 Date of International Manufacturers Enter into Hyperimmune Globulins Market
4.5.3 Manufacturers Hyperimmune Globulins Product Type and Application
4.5.4 Hepatitis B Immunoglobulins Market Sales of Hyperimmune Globulins by Manufacturer
4.5.5 Rabies Immunoglobulins Market Sales of Hyperimmune Globulins by Manufacturer
4.5.6 Tetanus Immunoglobulins Market Sales of Hyperimmune Globulins by Manufacturer
4.5.7 Rho(D) Immunoglobulins Market Sales of Hyperimmune Globulins by Manufacturer
4.5.8 Herpes Zoster Immune Globulin Market Sales of Hyperimmune Globulins by Manufacturer
4.5.9 Other Market Sales of Hyperimmune Globulins by Manufacturer
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 CSL Behring
5.1.1 CSL Behring Company Information
5.1.2 CSL Behring Description, Business Overview
5.1.3 CSL Behring Hyperimmune Globulins Products Offered
5.1.4 CSL Behring Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.1.5 CSL Behring Hyperimmune Globulins Sales by Product in 2024
5.1.6 CSL Behring Hyperimmune Globulins Sales by Application in 2024
5.1.7 CSL Behring Hyperimmune Globulins Sales by Geographic Area in 2024
5.1.8 CSL Behring Recent Developments
5.2 Grifols
5.2.1 Grifols Company Information
5.2.2 Grifols Description, Business Overview
5.2.3 Grifols Hyperimmune Globulins Products Offered
5.2.4 Grifols Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.2.5 Grifols Hyperimmune Globulins Sales by Product in 2024
5.2.6 Grifols Hyperimmune Globulins Sales by Application in 2024
5.2.7 Grifols Hyperimmune Globulins Sales by Geographic Area in 2024
5.2.8 Grifols Recent Developments
5.3 Biotest
5.3.1 Biotest Company Information
5.3.2 Biotest Description, Business Overview
5.3.3 Biotest Hyperimmune Globulins Products Offered
5.3.4 Biotest Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.3.5 Biotest Hyperimmune Globulins Sales by Product in 2024
5.3.6 Biotest Hyperimmune Globulins Sales by Application in 2024
5.3.7 Biotest Hyperimmune Globulins Sales by Geographic Area in 2024
5.3.8 Biotest Recent Developments
5.4 Kedrion
5.4.1 Kedrion Company Information
5.4.2 Kedrion Description, Business Overview
5.4.3 Kedrion Hyperimmune Globulins Products Offered
5.4.4 Kedrion Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.4.5 Kedrion Hyperimmune Globulins Sales by Product in 2024
5.4.6 Kedrion Hyperimmune Globulins Sales by Application in 2024
5.4.7 Kedrion Hyperimmune Globulins Sales by Geographic Area in 2024
5.4.8 Kedrion Recent Developments
5.5 CBPO
5.5.1 CBPO Company Information
5.5.2 CBPO Description, Business Overview
5.5.3 CBPO Hyperimmune Globulins Products Offered
5.5.4 CBPO Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.5.5 CBPO Hyperimmune Globulins Sales by Product in 2024
5.5.6 CBPO Hyperimmune Globulins Sales by Application in 2024
5.5.7 CBPO Hyperimmune Globulins Sales by Geographic Area in 2024
5.5.8 CBPO Recent Developments
5.6 Emergent (Cangene)
5.6.1 Emergent (Cangene) Company Information
5.6.2 Emergent (Cangene) Description, Business Overview
5.6.3 Emergent (Cangene) Hyperimmune Globulins Products Offered
5.6.4 Emergent (Cangene) Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.6.5 Emergent (Cangene) Hyperimmune Globulins Sales by Product in 2024
5.6.6 Emergent (Cangene) Hyperimmune Globulins Sales by Application in 2024
5.6.7 Emergent (Cangene) Hyperimmune Globulins Sales by Geographic Area in 2024
5.6.8 Emergent (Cangene) Recent Developments
5.7 Kamada
5.7.1 Kamada Company Information
5.7.2 Kamada Description, Business Overview
5.7.3 Kamada Hyperimmune Globulins Products Offered
5.7.4 Kamada Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.7.5 Kamada Hyperimmune Globulins Sales by Product in 2024
5.7.6 Kamada Hyperimmune Globulins Sales by Application in 2024
5.7.7 Kamada Hyperimmune Globulins Sales by Geographic Area in 2024
5.7.8 Kamada Recent Developments
5.8 CNBG
5.8.1 CNBG Company Information
5.8.2 CNBG Description, Business Overview
5.8.3 CNBG Hyperimmune Globulins Products Offered
5.8.4 CNBG Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.8.5 CNBG Hyperimmune Globulins Sales by Product in 2024
5.8.6 CNBG Hyperimmune Globulins Sales by Application in 2024
5.8.7 CNBG Hyperimmune Globulins Sales by Geographic Area in 2024
5.8.8 CNBG Recent Developments
5.9 Hualan Bio
5.9.1 Hualan Bio Company Information
5.9.2 Hualan Bio Description, Business Overview
5.9.3 Hualan Bio Hyperimmune Globulins Products Offered
5.9.4 Hualan Bio Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.9.5 Hualan Bio Hyperimmune Globulins Sales by Product in 2024
5.9.6 Hualan Bio Hyperimmune Globulins Sales by Application in 2024
5.9.7 Hualan Bio Hyperimmune Globulins Sales by Geographic Area in 2024
5.9.8 Hualan Bio Recent Developments
5.10 Shanghai RAAS
5.10.1 Shanghai RAAS Company Information
5.10.2 Shanghai RAAS Description, Business Overview
5.10.3 Shanghai RAAS Hyperimmune Globulins Products Offered
5.10.4 Shanghai RAAS Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.10.5 Shanghai RAAS Hyperimmune Globulins Sales by Product in 2024
5.10.6 Shanghai RAAS Hyperimmune Globulins Sales by Application in 2024
5.10.7 Shanghai RAAS Hyperimmune Globulins Sales by Geographic Area in 2024
5.10.8 Shanghai RAAS Recent Developments
5.11 Sichuan Yuanda Shuyang
5.11.1 Sichuan Yuanda Shuyang Company Information
5.11.2 Sichuan Yuanda Shuyang Description, Business Overview
5.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulins Products Offered
5.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.11.5 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales by Product in 2024
5.11.6 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales by Application in 2024
5.11.7 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales by Geographic Area in 2024
5.11.8 Sichuan Yuanda Shuyang Recent Developments
5.12 ADMA Biologics
5.12.1 ADMA Biologics Company Information
5.12.2 ADMA Biologics Description, Business Overview
5.12.3 ADMA Biologics Hyperimmune Globulins Products Offered
5.12.4 ADMA Biologics Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
5.12.5 ADMA Biologics Hyperimmune Globulins Sales by Product in 2024
5.12.6 ADMA Biologics Hyperimmune Globulins Sales by Application in 2024
5.12.7 ADMA Biologics Hyperimmune Globulins Sales by Geographic Area in 2024
5.12.8 ADMA Biologics Recent Developments
6 North America
6.1 North America Hyperimmune Globulins Market Size YoY Growth 2020-2031
6.2 North America Hyperimmune Globulins Market Facts & Figures by Country
6.2.1 North America Hyperimmune Globulins Sales by Country (2020-2031)
6.2.2 North America Hyperimmune Globulins Revenue by Country (2020-2031)
6.3 North America Hyperimmune Globulins Sales by Type (2020-2025)
6.4 North America Hyperimmune Globulins Sales by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Hyperimmune Globulins Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Hyperimmune Globulins Market Facts & Figures by Region
7.2.1 Asia-Pacific Hyperimmune Globulins Sales by Region (2020-2031)
7.2.2 Asia-Pacific Hyperimmune Globulins Revenue by Region (2020-2031)
7.3 Asia-Pacific Hyperimmune Globulins Sales by Type (2020-2025)
7.4 Asia-Pacific Hyperimmune Globulins Sales by Application (2020-2025)
8 Europe
8.1 Europe Hyperimmune Globulins Market Size YoY Growth 2020-2031
8.2 Europe Hyperimmune Globulins Market Facts & Figures by Country
8.2.1 Europe Hyperimmune Globulins Sales by Country (2020-2031)
8.2.2 Europe Hyperimmune Globulins Revenue by Country (2020-2031)
8.3 Europe Hyperimmune Globulins Sales by Type (2020-2025)
8.4 Europe Hyperimmune Globulins Sales by Application (2020-2025)
9 Latin America
9.1 Latin America Hyperimmune Globulins Market Size YoY Growth 2020-2031
9.2 Latin America Hyperimmune Globulins Market Facts & Figures by Country
9.2.1 Latin America Hyperimmune Globulins Sales by Country (2020-2031)
9.2.2 Latin America Hyperimmune Globulins Revenue by Country (2020-2031)
9.3 Latin America Hyperimmune Globulins Sales by Type (2020-2025)
9.4 Latin America Hyperimmune Globulins Sales by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Hyperimmune Globulins Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Hyperimmune Globulins Market Facts & Figures by Country
10.2.1 Middle East and Africa Hyperimmune Globulins Sales by Country (2020-2031)
10.2.2 Middle East and Africa Hyperimmune Globulins Revenue by Country (2020-2031)
10.3 Middle East and Africa Hyperimmune Globulins Sales by Type (2020-2025)
10.4 Middle East and Africa Hyperimmune Globulins Sales by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Hyperimmune Globulins Supply Chain Analysis
11.2 Hyperimmune Globulins Key Raw Materials and Upstream Suppliers
11.3 Hyperimmune Globulins Clients Analysis
11.4 Hyperimmune Globulins Sales Channel and Sales Model Analysis
11.4.1 Hyperimmune Globulins Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Hyperimmune Globulins Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Hyperimmune Globulins Distributors
12 Hyperimmune Globulins Market Dynamics
12.1 Hyperimmune Globulins Industry Trends
12.2 Hyperimmune Globulins Market Drivers
12.3 Hyperimmune Globulins Market Challenges
12.4 Hyperimmune Globulins Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Hyperimmune Globulins Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Hyperimmune Globulins Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Hyperimmune Globulins Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Hyperimmune Globulins Sales by Region (2020-2025) & (K Units)
Table 5. Global Hyperimmune Globulins Sales Forecast by Region (2026-2031) & (K Units)
Table 6. Global Hyperimmune Globulins Revenue by Region (2020-2025) & (US$ Million)
Table 7. Global Hyperimmune Globulins Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 8. Global Hyperimmune Globulins Sales Volume by Type (2020-2025) & (K Units)
Table 9. Global Hyperimmune Globulins Sales Volume by Type (2026-2031) & (K Units)
Table 10. Global Hyperimmune Globulins Revenue by Type (2020-2025) & (US$ Million)
Table 11. Global Hyperimmune Globulins Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 12. Global Hyperimmune Globulins Sales Volume by Application (2020-2025) & (K Units)
Table 13. Global Hyperimmune Globulins Sales Volume by Application (2026-2031) & (K Units)
Table 14. Global Hyperimmune Globulins Revenue by Application (2020-2025) & (US$ Million)
Table 15. Global Hyperimmune Globulins Revenue by Application (2026-2031) & (US$ Million)
Table 16. Global Hyperimmune Globulins Sales by Manufacturer (2020-2025) & (K Units)
Table 17. Global Hyperimmune Globulins Sales Share by Manufacturer (2020-2025)
Table 18. Hyperimmune Globulins Revenue by Manufacturer (2020-2025) & (US$ Million)
Table 19. Hyperimmune Globulins Revenue Share by Manufacturer (2020-2025)
Table 20. Key Manufacturers Hyperimmune Globulins Price (2020-2025) & (USD/Unit)
Table 21. Ranking of Global Top Hyperimmune Globulins Manufacturers by Revenue (US$ Million) in 2024
Table 22. Global Hyperimmune Globulins Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 23. Global Hyperimmune Globulins by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hyperimmune Globulins as of 2024)
Table 24. Hyperimmune Globulins Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Date of International Manufacturers Enter into Hyperimmune Globulins Market
Table 26. Manufacturers Hyperimmune Globulins Product Type and Application
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. CSL Behring Company Information
Table 29. CSL Behring Description and Business Overview
Table 30. CSL Behring Hyperimmune Globulins Product
Table 31. CSL Behring Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 32. CSL Behring Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 33. CSL Behring Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 34. CSL Behring Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 35. CSL Behring Recent Developments
Table 36. Grifols Company Information
Table 37. Grifols Description and Business Overview
Table 38. Grifols Hyperimmune Globulins Product
Table 39. Grifols Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 40. Grifols Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 41. Grifols Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 42. Grifols Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 43. Grifols Recent Developments
Table 44. Biotest Company Information
Table 45. Biotest Description and Business Overview
Table 46. Biotest Hyperimmune Globulins Product
Table 47. Biotest Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 48. Biotest Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 49. Biotest Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 50. Biotest Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 51. Biotest Recent Developments
Table 52. Kedrion Company Information
Table 53. Kedrion Description and Business Overview
Table 54. Kedrion Hyperimmune Globulins Product
Table 55. Kedrion Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 56. Kedrion Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 57. Kedrion Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 58. Kedrion Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 59. Kedrion Recent Developments
Table 60. CBPO Company Information
Table 61. CBPO Description and Business Overview
Table 62. CBPO Hyperimmune Globulins Product
Table 63. CBPO Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 64. CBPO Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 65. CBPO Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 66. CBPO Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 67. CBPO Recent Developments
Table 68. Emergent (Cangene) Company Information
Table 69. Emergent (Cangene) Description and Business Overview
Table 70. Emergent (Cangene) Hyperimmune Globulins Product
Table 71. Emergent (Cangene) Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 72. Emergent (Cangene) Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 73. Emergent (Cangene) Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 74. Emergent (Cangene) Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 75. Emergent (Cangene) Recent Developments
Table 76. Kamada Company Information
Table 77. Kamada Description and Business Overview
Table 78. Kamada Hyperimmune Globulins Product
Table 79. Kamada Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 80. Kamada Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 81. Kamada Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 82. Kamada Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 83. Kamada Recent Developments
Table 84. CNBG Company Information
Table 85. CNBG Description and Business Overview
Table 86. CNBG Hyperimmune Globulins Product
Table 87. CNBG Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. CNBG Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 89. CNBG Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 90. CNBG Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 91. CNBG Recent Developments
Table 92. Hualan Bio Company Information
Table 93. Hualan Bio Description and Business Overview
Table 94. Hualan Bio Hyperimmune Globulins Product
Table 95. Hualan Bio Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Hualan Bio Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 97. Hualan Bio Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 98. Hualan Bio Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 99. Hualan Bio Recent Developments
Table 100. Shanghai RAAS Company Information
Table 101. Shanghai RAAS Description and Business Overview
Table 102. Shanghai RAAS Hyperimmune Globulins Product
Table 103. Shanghai RAAS Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 104. Shanghai RAAS Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 105. Shanghai RAAS Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 106. Shanghai RAAS Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 107. Shanghai RAAS Recent Developments
Table 108. Sichuan Yuanda Shuyang Company Information
Table 109. Sichuan Yuanda Shuyang Description and Business Overview
Table 110. Sichuan Yuanda Shuyang Hyperimmune Globulins Product
Table 111. Sichuan Yuanda Shuyang Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 112. Sichuan Yuanda Shuyang Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 113. Sichuan Yuanda Shuyang Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 114. Sichuan Yuanda Shuyang Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 115. Sichuan Yuanda Shuyang Recent Developments
Table 116. ADMA Biologics Company Information
Table 117. ADMA Biologics Description and Business Overview
Table 118. ADMA Biologics Hyperimmune Globulins Product
Table 119. ADMA Biologics Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 120. ADMA Biologics Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 121. ADMA Biologics Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 122. ADMA Biologics Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 123. ADMA Biologics Recent Developments
Table 124. North America Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)
Table 125. North America Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)
Table 126. North America Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)
Table 127. North America Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)
Table 128. North America Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)
Table 129. North America Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)
Table 130. Asia-Pacific Hyperimmune Globulins Sales by Region (2020-2025) & (K Units)
Table 131. Asia-Pacific Hyperimmune Globulins Sales by Region (2026-2031) & (K Units)
Table 132. Asia-Pacific Hyperimmune Globulins Revenue by Region (2020-2025) & (US$ Million)
Table 133. Asia-Pacific Hyperimmune Globulins Revenue by Region (2026-2031) & (US$ Million)
Table 134. Asia-Pacific Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)
Table 135. Asia-Pacific Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)
Table 136. Europe Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)
Table 137. Europe Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)
Table 138. Europe Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)
Table 139. Europe Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)
Table 140. Europe Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)
Table 141. Europe Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)
Table 142. Latin America Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)
Table 143. Latin America Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)
Table 144. Latin America Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)
Table 145. Latin America Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)
Table 146. Latin America Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)
Table 147. Latin America Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)
Table 148. Middle East and Africa Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)
Table 149. Middle East and Africa Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)
Table 150. Middle East and Africa Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)
Table 151. Middle East and Africa Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)
Table 152. Middle East and Africa Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)
Table 153. Middle East and Africa Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)
Table 154. Hyperimmune Globulins Key Raw Materials, Industry Status and Trend
Table 155. Hyperimmune Globulins Key Raw Materials and Upstream Suppliers
Table 156. Hyperimmune Globulins Clients Status and Trend
Table 157. Hyperimmune Globulins Typical Clients
Table 158. Hyperimmune Globulins Distributors
Table 159. Hyperimmune Globulins Market Trends
Table 160. Hyperimmune Globulins Market Drivers
Table 161. Hyperimmune Globulins Market Challenges
Table 162. Hyperimmune Globulins Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
Table 166. QYR Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Hyperimmune Globulins Product Picture
Figure 2. Global Hyperimmune Globulins Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Hyperimmune Globulins Sales Market Share by Type in 2024 & 2031
Figure 4. Hepatitis B Immunoglobulins Product Picture
Figure 5. Rabies Immunoglobulins Product Picture
Figure 6. Tetanus Immunoglobulins Product Picture
Figure 7. Rho(D) Immunoglobulins Product Picture
Figure 8. Herpes Zoster Immune Globulin Product Picture
Figure 9. Other Product Picture
Figure 10. Global Hyperimmune Globulins Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 11. Global Hyperimmune Globulins Sales Market Share by Application in 2024 & 2031
Figure 12. Government Institutions
Figure 13. Private Sector
Figure 14. Other
Figure 15. Hyperimmune Globulins Report Years Considered
Figure 16. Global Hyperimmune Globulins Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Hyperimmune Globulins Market Size 2020-2031 (US$ Million)
Figure 18. Global Hyperimmune Globulins Sales 2020-2031 (K Units)
Figure 19. Global Hyperimmune Globulins Sales Market Share Forecast by Region (2020-2031)
Figure 20. Global Hyperimmune Globulins Revenue Market Share by Region (2020-2031)
Figure 21. Global Hyperimmune Globulins Sales Market Share Forecast by Type (2020-2031)
Figure 22. Global Hyperimmune Globulins Revenue Market Share Forecast by Type (2020-2031)
Figure 23. Hyperimmune Globulins Average Selling Price (ASP) by Type (2020-2025) & (USD/Unit)
Figure 24. Global Hyperimmune Globulins Sales Market Share Forecast by Application (2020-2031)
Figure 25. Global Hyperimmune Globulins Revenue Market Share Forecast by Application (2020-2031)
Figure 26. Hyperimmune Globulins Average Selling Price (ASP) by Application (2020-2025) & (USD/Unit)
Figure 27. Hepatitis B Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031
Figure 28. Rabies Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031
Figure 29. Tetanus Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031
Figure 30. Rho(D) Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031
Figure 31. Herpes Zoster Immune Globulin of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031
Figure 32. Other of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031
Figure 33. Global Hyperimmune Globulins Sales Share by Manufacturer in 2024
Figure 34. Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 35. Hepatitis B Immunoglobulins Market Sales Proportion by Manufacturer in 2024
Figure 36. Rabies Immunoglobulins Market Sales Proportion by Manufacturer in 2024
Figure 37. Tetanus Immunoglobulins Market Sales Proportion by Manufacturer in 2024
Figure 38. Rho(D) Immunoglobulins Market Sales Proportion by Manufacturer in 2024
Figure 39. Herpes Zoster Immune Globulin Market Sales Proportion by Manufacturer in 2024
Figure 40. Other Market Sales Proportion by Manufacturer in 2024
Figure 41. North America Hyperimmune Globulins Revenue 2020-2031 (US$ Million)
Figure 42. North America Hyperimmune Globulins Sales Market Share by Type (2020-2025)
Figure 43. North America Hyperimmune Globulins Sales Market Share by Application (2020-2025)
Figure 44. Asia-Pacific Hyperimmune Globulins Revenue 2020-2031 (US$ Million)
Figure 45. Asia-Pacific Hyperimmune Globulins Sales Market Share by Region (2020-2031)
Figure 46. Asia-Pacific Hyperimmune Globulins Revenue Market Share by Region (2020-2031)
Figure 47. Asia-Pacific Hyperimmune Globulins Sales Market Share by Type (2020-2025)
Figure 48. Asia-Pacific Hyperimmune Globulins Sales Market Share by Application (2020-2025)
Figure 49. Europe Hyperimmune Globulins Revenue Growth Rate 2020-2031 (US$ Million)
Figure 50. Europe Hyperimmune Globulins Sales Market Share by Country (2020-2031)
Figure 51. Europe Hyperimmune Globulins Revenue Market Share by Country (2020-2031)
Figure 52. Europe Hyperimmune Globulins Sales Market Share by Type (2020-2025)
Figure 53. Europe Hyperimmune Globulins Sales Market Share by Application (2020-2025)
Figure 54. Latin America Hyperimmune Globulins Revenue Growth Rate 2020-2031 (US$ Million)
Figure 55. Latin America Hyperimmune Globulins Sales Market Share by Country (2020-2031)
Figure 56. Latin America Hyperimmune Globulins Revenue Market Share by Country (2020-2025)
Figure 57. Latin America Hyperimmune Globulins Sales Market Share by Type (2020-2025)
Figure 58. Latin America Hyperimmune Globulins Sales Market Share by Application (2020-2025)
Figure 59. Middle East and Africa Hyperimmune Globulins Revenue Growth Rate 2020-2031 (US$ Million)
Figure 60. Middle East and Africa Hyperimmune Globulins Sales Market Share by Country (2020-2031)
Figure 61. Middle East and Africa Hyperimmune Globulins Revenue Market Share by Country (2020-2031)
Figure 62. Middle East and Africa Hyperimmune Globulins Sales Market Share by Type (2020-2025)
Figure 63. Middle East and Africa Hyperimmune Globulins Sales Market Share by Application (2020-2025)
Figure 64. Hyperimmune Globulins Supply Chain (Upstream and Downstream Market)
Figure 65. Global Production Market Share of Hyperimmune Globulins Raw Materials by Region in 2024
Figure 66. Hyperimmune Globulins Distribution Channels
Figure 67. Global Hyperimmune Globulins Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 68. Global Hyperimmune Globulins Percentage 2020-2031: Online Sales VS Offline Sales
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Table 1. Global Hyperimmune Globulins Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Hyperimmune Globulins Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Hyperimmune Globulins Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Hyperimmune Globulins Sales by Region (2020-2025) & (K Units)
Table 5. Global Hyperimmune Globulins Sales Forecast by Region (2026-2031) & (K Units)
Table 6. Global Hyperimmune Globulins Revenue by Region (2020-2025) & (US$ Million)
Table 7. Global Hyperimmune Globulins Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 8. Global Hyperimmune Globulins Sales Volume by Type (2020-2025) & (K Units)
Table 9. Global Hyperimmune Globulins Sales Volume by Type (2026-2031) & (K Units)
Table 10. Global Hyperimmune Globulins Revenue by Type (2020-2025) & (US$ Million)
Table 11. Global Hyperimmune Globulins Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 12. Global Hyperimmune Globulins Sales Volume by Application (2020-2025) & (K Units)
Table 13. Global Hyperimmune Globulins Sales Volume by Application (2026-2031) & (K Units)
Table 14. Global Hyperimmune Globulins Revenue by Application (2020-2025) & (US$ Million)
Table 15. Global Hyperimmune Globulins Revenue by Application (2026-2031) & (US$ Million)
Table 16. Global Hyperimmune Globulins Sales by Manufacturer (2020-2025) & (K Units)
Table 17. Global Hyperimmune Globulins Sales Share by Manufacturer (2020-2025)
Table 18. Hyperimmune Globulins Revenue by Manufacturer (2020-2025) & (US$ Million)
Table 19. Hyperimmune Globulins Revenue Share by Manufacturer (2020-2025)
Table 20. Key Manufacturers Hyperimmune Globulins Price (2020-2025) & (USD/Unit)
Table 21. Ranking of Global Top Hyperimmune Globulins Manufacturers by Revenue (US$ Million) in 2024
Table 22. Global Hyperimmune Globulins Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 23. Global Hyperimmune Globulins by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hyperimmune Globulins as of 2024)
Table 24. Hyperimmune Globulins Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Date of International Manufacturers Enter into Hyperimmune Globulins Market
Table 26. Manufacturers Hyperimmune Globulins Product Type and Application
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. CSL Behring Company Information
Table 29. CSL Behring Description and Business Overview
Table 30. CSL Behring Hyperimmune Globulins Product
Table 31. CSL Behring Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 32. CSL Behring Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 33. CSL Behring Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 34. CSL Behring Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 35. CSL Behring Recent Developments
Table 36. Grifols Company Information
Table 37. Grifols Description and Business Overview
Table 38. Grifols Hyperimmune Globulins Product
Table 39. Grifols Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 40. Grifols Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 41. Grifols Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 42. Grifols Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 43. Grifols Recent Developments
Table 44. Biotest Company Information
Table 45. Biotest Description and Business Overview
Table 46. Biotest Hyperimmune Globulins Product
Table 47. Biotest Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 48. Biotest Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 49. Biotest Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 50. Biotest Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 51. Biotest Recent Developments
Table 52. Kedrion Company Information
Table 53. Kedrion Description and Business Overview
Table 54. Kedrion Hyperimmune Globulins Product
Table 55. Kedrion Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 56. Kedrion Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 57. Kedrion Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 58. Kedrion Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 59. Kedrion Recent Developments
Table 60. CBPO Company Information
Table 61. CBPO Description and Business Overview
Table 62. CBPO Hyperimmune Globulins Product
Table 63. CBPO Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 64. CBPO Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 65. CBPO Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 66. CBPO Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 67. CBPO Recent Developments
Table 68. Emergent (Cangene) Company Information
Table 69. Emergent (Cangene) Description and Business Overview
Table 70. Emergent (Cangene) Hyperimmune Globulins Product
Table 71. Emergent (Cangene) Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 72. Emergent (Cangene) Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 73. Emergent (Cangene) Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 74. Emergent (Cangene) Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 75. Emergent (Cangene) Recent Developments
Table 76. Kamada Company Information
Table 77. Kamada Description and Business Overview
Table 78. Kamada Hyperimmune Globulins Product
Table 79. Kamada Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 80. Kamada Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 81. Kamada Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 82. Kamada Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 83. Kamada Recent Developments
Table 84. CNBG Company Information
Table 85. CNBG Description and Business Overview
Table 86. CNBG Hyperimmune Globulins Product
Table 87. CNBG Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. CNBG Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 89. CNBG Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 90. CNBG Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 91. CNBG Recent Developments
Table 92. Hualan Bio Company Information
Table 93. Hualan Bio Description and Business Overview
Table 94. Hualan Bio Hyperimmune Globulins Product
Table 95. Hualan Bio Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Hualan Bio Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 97. Hualan Bio Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 98. Hualan Bio Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 99. Hualan Bio Recent Developments
Table 100. Shanghai RAAS Company Information
Table 101. Shanghai RAAS Description and Business Overview
Table 102. Shanghai RAAS Hyperimmune Globulins Product
Table 103. Shanghai RAAS Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 104. Shanghai RAAS Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 105. Shanghai RAAS Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 106. Shanghai RAAS Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 107. Shanghai RAAS Recent Developments
Table 108. Sichuan Yuanda Shuyang Company Information
Table 109. Sichuan Yuanda Shuyang Description and Business Overview
Table 110. Sichuan Yuanda Shuyang Hyperimmune Globulins Product
Table 111. Sichuan Yuanda Shuyang Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 112. Sichuan Yuanda Shuyang Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 113. Sichuan Yuanda Shuyang Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 114. Sichuan Yuanda Shuyang Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 115. Sichuan Yuanda Shuyang Recent Developments
Table 116. ADMA Biologics Company Information
Table 117. ADMA Biologics Description and Business Overview
Table 118. ADMA Biologics Hyperimmune Globulins Product
Table 119. ADMA Biologics Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 120. ADMA Biologics Sales Proportion of Hyperimmune Globulins by Product in 2024
Table 121. ADMA Biologics Sales Proportion of Hyperimmune Globulins by Application in 2024
Table 122. ADMA Biologics Sales Proportion of Hyperimmune Globulins by Geographic Area in 2024
Table 123. ADMA Biologics Recent Developments
Table 124. North America Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)
Table 125. North America Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)
Table 126. North America Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)
Table 127. North America Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)
Table 128. North America Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)
Table 129. North America Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)
Table 130. Asia-Pacific Hyperimmune Globulins Sales by Region (2020-2025) & (K Units)
Table 131. Asia-Pacific Hyperimmune Globulins Sales by Region (2026-2031) & (K Units)
Table 132. Asia-Pacific Hyperimmune Globulins Revenue by Region (2020-2025) & (US$ Million)
Table 133. Asia-Pacific Hyperimmune Globulins Revenue by Region (2026-2031) & (US$ Million)
Table 134. Asia-Pacific Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)
Table 135. Asia-Pacific Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)
Table 136. Europe Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)
Table 137. Europe Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)
Table 138. Europe Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)
Table 139. Europe Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)
Table 140. Europe Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)
Table 141. Europe Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)
Table 142. Latin America Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)
Table 143. Latin America Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)
Table 144. Latin America Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)
Table 145. Latin America Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)
Table 146. Latin America Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)
Table 147. Latin America Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)
Table 148. Middle East and Africa Hyperimmune Globulins Sales by Country (2020-2025) & (K Units)
Table 149. Middle East and Africa Hyperimmune Globulins Sales by Country (2026-2031) & (K Units)
Table 150. Middle East and Africa Hyperimmune Globulins Revenue by Country (2020-2025) & (US$ Million)
Table 151. Middle East and Africa Hyperimmune Globulins Revenue by Country (2026-2031) & (US$ Million)
Table 152. Middle East and Africa Hyperimmune Globulins Sales by Type (2020-2025) & (K Units)
Table 153. Middle East and Africa Hyperimmune Globulins Sales by Application (2020-2025) & (K Units)
Table 154. Hyperimmune Globulins Key Raw Materials, Industry Status and Trend
Table 155. Hyperimmune Globulins Key Raw Materials and Upstream Suppliers
Table 156. Hyperimmune Globulins Clients Status and Trend
Table 157. Hyperimmune Globulins Typical Clients
Table 158. Hyperimmune Globulins Distributors
Table 159. Hyperimmune Globulins Market Trends
Table 160. Hyperimmune Globulins Market Drivers
Table 161. Hyperimmune Globulins Market Challenges
Table 162. Hyperimmune Globulins Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
Table 166. QYR Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Hyperimmune Globulins Product Picture
Figure 2. Global Hyperimmune Globulins Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Hyperimmune Globulins Sales Market Share by Type in 2024 & 2031
Figure 4. Hepatitis B Immunoglobulins Product Picture
Figure 5. Rabies Immunoglobulins Product Picture
Figure 6. Tetanus Immunoglobulins Product Picture
Figure 7. Rho(D) Immunoglobulins Product Picture
Figure 8. Herpes Zoster Immune Globulin Product Picture
Figure 9. Other Product Picture
Figure 10. Global Hyperimmune Globulins Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 11. Global Hyperimmune Globulins Sales Market Share by Application in 2024 & 2031
Figure 12. Government Institutions
Figure 13. Private Sector
Figure 14. Other
Figure 15. Hyperimmune Globulins Report Years Considered
Figure 16. Global Hyperimmune Globulins Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Hyperimmune Globulins Market Size 2020-2031 (US$ Million)
Figure 18. Global Hyperimmune Globulins Sales 2020-2031 (K Units)
Figure 19. Global Hyperimmune Globulins Sales Market Share Forecast by Region (2020-2031)
Figure 20. Global Hyperimmune Globulins Revenue Market Share by Region (2020-2031)
Figure 21. Global Hyperimmune Globulins Sales Market Share Forecast by Type (2020-2031)
Figure 22. Global Hyperimmune Globulins Revenue Market Share Forecast by Type (2020-2031)
Figure 23. Hyperimmune Globulins Average Selling Price (ASP) by Type (2020-2025) & (USD/Unit)
Figure 24. Global Hyperimmune Globulins Sales Market Share Forecast by Application (2020-2031)
Figure 25. Global Hyperimmune Globulins Revenue Market Share Forecast by Application (2020-2031)
Figure 26. Hyperimmune Globulins Average Selling Price (ASP) by Application (2020-2025) & (USD/Unit)
Figure 27. Hepatitis B Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031
Figure 28. Rabies Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031
Figure 29. Tetanus Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031
Figure 30. Rho(D) Immunoglobulins of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031
Figure 31. Herpes Zoster Immune Globulin of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031
Figure 32. Other of Hyperimmune Globulins Revenue Market Share by Application, 2024 VS 2031
Figure 33. Global Hyperimmune Globulins Sales Share by Manufacturer in 2024
Figure 34. Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 35. Hepatitis B Immunoglobulins Market Sales Proportion by Manufacturer in 2024
Figure 36. Rabies Immunoglobulins Market Sales Proportion by Manufacturer in 2024
Figure 37. Tetanus Immunoglobulins Market Sales Proportion by Manufacturer in 2024
Figure 38. Rho(D) Immunoglobulins Market Sales Proportion by Manufacturer in 2024
Figure 39. Herpes Zoster Immune Globulin Market Sales Proportion by Manufacturer in 2024
Figure 40. Other Market Sales Proportion by Manufacturer in 2024
Figure 41. North America Hyperimmune Globulins Revenue 2020-2031 (US$ Million)
Figure 42. North America Hyperimmune Globulins Sales Market Share by Type (2020-2025)
Figure 43. North America Hyperimmune Globulins Sales Market Share by Application (2020-2025)
Figure 44. Asia-Pacific Hyperimmune Globulins Revenue 2020-2031 (US$ Million)
Figure 45. Asia-Pacific Hyperimmune Globulins Sales Market Share by Region (2020-2031)
Figure 46. Asia-Pacific Hyperimmune Globulins Revenue Market Share by Region (2020-2031)
Figure 47. Asia-Pacific Hyperimmune Globulins Sales Market Share by Type (2020-2025)
Figure 48. Asia-Pacific Hyperimmune Globulins Sales Market Share by Application (2020-2025)
Figure 49. Europe Hyperimmune Globulins Revenue Growth Rate 2020-2031 (US$ Million)
Figure 50. Europe Hyperimmune Globulins Sales Market Share by Country (2020-2031)
Figure 51. Europe Hyperimmune Globulins Revenue Market Share by Country (2020-2031)
Figure 52. Europe Hyperimmune Globulins Sales Market Share by Type (2020-2025)
Figure 53. Europe Hyperimmune Globulins Sales Market Share by Application (2020-2025)
Figure 54. Latin America Hyperimmune Globulins Revenue Growth Rate 2020-2031 (US$ Million)
Figure 55. Latin America Hyperimmune Globulins Sales Market Share by Country (2020-2031)
Figure 56. Latin America Hyperimmune Globulins Revenue Market Share by Country (2020-2025)
Figure 57. Latin America Hyperimmune Globulins Sales Market Share by Type (2020-2025)
Figure 58. Latin America Hyperimmune Globulins Sales Market Share by Application (2020-2025)
Figure 59. Middle East and Africa Hyperimmune Globulins Revenue Growth Rate 2020-2031 (US$ Million)
Figure 60. Middle East and Africa Hyperimmune Globulins Sales Market Share by Country (2020-2031)
Figure 61. Middle East and Africa Hyperimmune Globulins Revenue Market Share by Country (2020-2031)
Figure 62. Middle East and Africa Hyperimmune Globulins Sales Market Share by Type (2020-2025)
Figure 63. Middle East and Africa Hyperimmune Globulins Sales Market Share by Application (2020-2025)
Figure 64. Hyperimmune Globulins Supply Chain (Upstream and Downstream Market)
Figure 65. Global Production Market Share of Hyperimmune Globulins Raw Materials by Region in 2024
Figure 66. Hyperimmune Globulins Distribution Channels
Figure 67. Global Hyperimmune Globulins Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 68. Global Hyperimmune Globulins Percentage 2020-2031: Online Sales VS Offline Sales
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Medical Waste Fluid Solidifier Market Research Report 2025
Jun 12, 25
Global Metalized Bubble Material Market Research Report 2025
Jun 12, 25
Global 70% Isopropyl Rubbing Alcohol Market Research Report 2025
Jun 12, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232